Cargando…

Safety of artemether-lumefantrine exposure in first trimester of pregnancy: an observational cohort

BACKGROUND: There is limited data available regarding safety profile of artemisinins in early pregnancy. They are, therefore, not recommended by WHO as a first-line treatment for malaria in first trimester due to associated embryo-foetal toxicity in animal studies. The study assessed birth outcome a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mosha, Dominic, Mazuguni, Festo, Mrema, Sigilbert, Sevene, Esperanca, Abdulla, Salim, Genton, Blaise
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040412/ https://www.ncbi.nlm.nih.gov/pubmed/24884890 http://dx.doi.org/10.1186/1475-2875-13-197

Ejemplares similares

Medication exposure during pregnancy: a pilot pharmacovigilance system using health and demographic surveillance platform
por: Mosha, Dominic, et al.
Publicado: (2014)

Exposure to artemether-lumefantrine (Coartem®) in first trimester pregnancy in an observational study in Zambia
por: Manyando, Christine, et al.
Publicado: (2015)

Optimal timing of primaquine to reduce Plasmodium falciparum gametocyte carriage when co-administered with artemether–lumefantrine
por: Shekalaghe, Seif, et al.
Publicado: (2020)

Experience of safety monitoring in the context of a prospective observational study of artemether-lumefantrine in rural Tanzania: lessons learned for pharmacovigilance reporting
por: Kabanywany, Abdunoor Mulokozi, et al.
Publicado: (2010)

Experience of safety monitoring in the context of a prospective observational study of artemether-lumefantrine in rural Tanzania: lessons learned for pharmacovigilance reporting
por: Kabanywanyi, Abdunoor M, et al.
Publicado: (2010)

Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children
por: Abdulla, Salim, et al.
Publicado: (2009)

Appropriateness of malaria diagnosis and treatment for fever episodes according to patient history and anti-malarial blood measurement: a cross-sectional survey from Tanzania
por: Gallay, Joanna, et al.
Publicado: (2018)

Predictors of residual antimalarial drugs in the blood in community surveys in Tanzania
por: Gallay, Joanna, et al.
Publicado: (2018)

Safety monitoring experience of single-low dose primaquine co-administered with artemether–lumefantrine among providers and patients in routine healthcare practice: a qualitative study in Eastern Tanzania
por: Mosha, Dominic, et al.
Publicado: (2021)

Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children
por: Huang, Liusheng, et al.
Publicado: (2017)

Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients
por: Staehli Hodel, Eva Maria, et al.
Publicado: (2013)

Development of a dissolution method for lumefantrine and artemether in immediate release fixed dose artemether/lumefantrine tablets
por: Belew, Sileshi, et al.
Publicado: (2020)

Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania
por: Kabanywanyi, Abdunoor M, et al.
Publicado: (2010)

The clinical efficacy of artemether/lumefantrine (Coartem(®))
por: Makanga, Michael, et al.
Publicado: (2009)

Severe Acute Malnutrition Results in Lower Lumefantrine Exposure in Children Treated With Artemether‐Lumefantrine for Uncomplicated Malaria
por: Chotsiri, Palang, et al.
Publicado: (2019)

Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine
por: Ali, Shabana, et al.
Publicado: (2010)

Assessment of the impact of availability and readiness of malaria services on uptake of intermittent preventive treatment in pregnancy (IPTp) provided during ANC visits in Tanzania
por: Bajaria, Shraddha, et al.
Publicado: (2019)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults
por: Chughlay, M. Farouk, et al.
Publicado: (2022)

Quality Assessment of Artemether-Lumefantrine Samples and Artemether Injections Sold in the Cape Coast Metropolis
por: Prah, James, et al.
Publicado: (2016)

A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy
por: Manyando, Christine, et al.
Publicado: (2012)

Safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy: a systematic review
por: Manyando, Christine, et al.
Publicado: (2012)

Artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria
por: Ehrhardt, Stephan, et al.
Publicado: (2009)

Continued Low Efficacy of Artemether-Lumefantrine in Angola in 2019
por: Dimbu, Pedro Rafael, et al.
Publicado: (2021)

First-trimester artemisinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: A meta-analysis of observational studies
por: Dellicour, Stephanie, et al.
Publicado: (2017)

Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria
por: Tchaparian, Eskouhie, et al.
Publicado: (2016)

Update on the efficacy, effectiveness and safety of artemether–lumefantrine combination therapy for treatment of uncomplicated malaria
por: Byakika-Kibwika, Pauline, et al.
Publicado: (2010)

Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects
por: Abdulla, Salim, et al.
Publicado: (2010)

The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether-lumefantrine: a review of the evidence
por: Premji, Zulfiqarali G, et al.
Publicado: (2008)

In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated falciparum malaria in children: a multisite, open-label, two-cohort, clinical trial in Mozambique
por: Nhama, Abel, et al.
Publicado: (2014)

Increased systemic exposures of artemether and dihydroartemisinin in infants under 5 kg with uncomplicated Plasmodium falciparum malaria treated with artemether-lumefantrine (Coartem®)
por: Tiono, Alfred B, et al.
Publicado: (2015)

The Use of Artemether-Lumefantrine for the Treatment of Uncomplicated Plasmodium vivax Malaria
por: Bassat, Quique
Publicado: (2011)

Therapeutic efficacy of artemether-lumefantrine in uncomplicated falciparum malaria in India
por: Valecha, Neena, et al.
Publicado: (2009)

Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine
por: Walimbwa, Stephen I., et al.
Publicado: (2019)

Artemether/Lumefantrine for the Treatment of P. malariae in a Patient on Hemodialysis
por: Patrocínio-Jesus, Rita, et al.
Publicado: (2019)

Monitoring of the Sensitivity In Vivo of Plasmodium falciparum to Artemether-Lumefantrine in Mali
por: Diarra, Modibo, et al.
Publicado: (2021)

Adverse reaction to Coartem (artemether/lumefantrine) resulting in oculogyric crisis
por: Amponsah, Emmanuel Kofi, et al.
Publicado: (2021)

Artemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi
por: Nyangulu, Wongani, et al.
Publicado: (2023)

Pharmacopeial quality of artemether–lumefantrine anti-malarial agents in Uganda
por: Ocan, Moses, et al.
Publicado: (2023)

Triple therapy with artemether–lumefantrine plus amodiaquine versus artemether–lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial
por: Peto, Thomas J, et al.
Publicado: (2022)

Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults
por: Byakika-Kibwika, Pauline, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_dm9asbr2dusi5n8vetbcbsb5lh